An impurity was found in a lot of antidepressant Fluoxetine tolife, announced the National Authority of Medicine and Health Products on Monday.
Infarmed ordered on Monday the withdrawal of the market from a plot of the drug Fluxetina Tolife, for the treatment of depression, because an impurity was found, announced the National Authority of Medicine and Health Products.
Numa Infarmed said that the company Towa Pharmaceutical, SA will make voluntary collections of the 23kn163A of the drug Fluxetina 20 mg of 60 capsules, “for being detected an analytical result above acceptable limits for impurity.”
The drug authority appeals to entities that have this batch of medicines in “Stock” so as not to sell, dispense or administer, and must proceed to its return.
It advises patients who are using medications belonging to these lots not to interrupt the treatment and contact the doctor as soon as possible, to replace with another lot or an alternative medicine.
